These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

237 related items for PubMed ID: 33459596

  • 1. Loss of FLCN-FNIP1/2 induces a non-canonical interferon response in human renal tubular epithelial cells.
    Glykofridis IE, Knol JC, Balk JA, Westland D, Pham TV, Piersma SR, Lougheed SM, Derakhshan S, Veen P, Rooimans MA, van Mil SE, Böttger F, Poddighe PJ, van de Beek I, Drost J, Zwartkruis FJ, de Menezes RX, Meijers-Heijboer HE, Houweling AC, Jimenez CR, Wolthuis RM.
    Elife; 2021 Jan 18; 10():. PubMed ID: 33459596
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Interaction of folliculin (Birt-Hogg-Dubé gene product) with a novel Fnip1-like (FnipL/Fnip2) protein.
    Takagi Y, Kobayashi T, Shiono M, Wang L, Piao X, Sun G, Zhang D, Abe M, Hagiwara Y, Takahashi K, Hino O.
    Oncogene; 2008 Sep 11; 27(40):5339-47. PubMed ID: 18663353
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Folliculin variants linked to Birt-Hogg-Dubé syndrome are targeted for proteasomal degradation.
    Clausen L, Stein A, Grønbæk-Thygesen M, Nygaard L, Søltoft CL, Nielsen SV, Lisby M, Ravid T, Lindorff-Larsen K, Hartmann-Petersen R.
    PLoS Genet; 2020 Nov 11; 16(11):e1009187. PubMed ID: 33137092
    [Abstract] [Full Text] [Related]

  • 6. Nutrient-induced FNIP degradation by SCFβ-TRCP regulates FLCN complex localization and promotes renal cancer progression.
    Nagashima K, Fukushima H, Shimizu K, Yamada A, Hidaka M, Hasumi H, Ikebe T, Fukumoto S, Okabe K, Inuzuka H.
    Oncotarget; 2017 Feb 07; 8(6):9947-9960. PubMed ID: 28039480
    [Abstract] [Full Text] [Related]

  • 7. FLCN: The causative gene for Birt-Hogg-Dubé syndrome.
    Schmidt LS, Linehan WM.
    Gene; 2018 Jan 15; 640():28-42. PubMed ID: 28970150
    [Abstract] [Full Text] [Related]

  • 8. Identification and characterization of a novel folliculin-interacting protein FNIP2.
    Hasumi H, Baba M, Hong SB, Hasumi Y, Huang Y, Yao M, Valera VA, Linehan WM, Schmidt LS.
    Gene; 2008 May 31; 415(1-2):60-7. PubMed ID: 18403135
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Distinctive expression patterns of glycoprotein non-metastatic B and folliculin in renal tumors in patients with Birt-Hogg-Dubé syndrome.
    Furuya M, Hong SB, Tanaka R, Kuroda N, Nagashima Y, Nagahama K, Suyama T, Yao M, Nakatani Y.
    Cancer Sci; 2015 Mar 31; 106(3):315-23. PubMed ID: 25594584
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Birt-Hogg-Dubé syndrome: from gene discovery to molecularly targeted therapies.
    Schmidt LS.
    Fam Cancer; 2013 Sep 31; 12(3):357-64. PubMed ID: 23108783
    [Abstract] [Full Text] [Related]

  • 13. Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling.
    Baba M, Hong SB, Sharma N, Warren MB, Nickerson ML, Iwamatsu A, Esposito D, Gillette WK, Hopkins RF, Hartley JL, Furihata M, Oishi S, Zhen W, Burke TR, Linehan WM, Schmidt LS, Zbar B.
    Proc Natl Acad Sci U S A; 2006 Oct 17; 103(42):15552-7. PubMed ID: 17028174
    [Abstract] [Full Text] [Related]

  • 14. Inactivation of the FLCN tumor suppressor gene induces TFE3 transcriptional activity by increasing its nuclear localization.
    Hong SB, Oh H, Valera VA, Baba M, Schmidt LS, Linehan WM.
    PLoS One; 2010 Dec 29; 5(12):e15793. PubMed ID: 21209915
    [Abstract] [Full Text] [Related]

  • 15. Clinical Features, Genetics and Potential Therapeutic Approaches for Birt-Hogg-Dubé Syndrome.
    Schmidt LS, Linehan WM.
    Expert Opin Orphan Drugs; 2015 Dec 29; 3(1):15-29. PubMed ID: 26581862
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Renal cancer and pneumothorax risk in Birt-Hogg-Dubé syndrome; an analysis of 115 FLCN mutation carriers from 35 BHD families.
    Houweling AC, Gijezen LM, Jonker MA, van Doorn MB, Oldenburg RA, van Spaendonck-Zwarts KY, Leter EM, van Os TA, van Grieken NC, Jaspars EH, de Jong MM, Bongers EM, Johannesma PC, Postmus PE, van Moorselaar RJ, van Waesberghe JH, Starink TM, van Steensel MA, Gille JJ, Menko FH.
    Br J Cancer; 2011 Dec 06; 105(12):1912-9. PubMed ID: 22146830
    [Abstract] [Full Text] [Related]

  • 18. Birt-Hogg-Dube syndrome: clinicopathological features of the lung.
    Furuya M, Nakatani Y.
    J Clin Pathol; 2013 Mar 06; 66(3):178-86. PubMed ID: 23223565
    [Abstract] [Full Text] [Related]

  • 19. Folliculin impairs breast tumor growth by repressing TFE3-dependent induction of the Warburg effect and angiogenesis.
    El-Houjeiri L, Biondini M, Paquette M, Kuasne H, Pacis A, Park M, Siegel PM, Pause A.
    J Clin Invest; 2021 Nov 15; 131(22):. PubMed ID: 34779410
    [Abstract] [Full Text] [Related]

  • 20. Tumor suppressor FLCN inhibits tumorigenesis of a FLCN-null renal cancer cell line and regulates expression of key molecules in TGF-beta signaling.
    Hong SB, Oh H, Valera VA, Stull J, Ngo DT, Baba M, Merino MJ, Linehan WM, Schmidt LS.
    Mol Cancer; 2010 Jun 23; 9():160. PubMed ID: 20573232
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.